Beijing Biostar Technologies Ltd (HKG: 2563), a synthetic biology-driven anti-tumor drug specialist that made its debut in Hong Kong last month, has entered into a market promotion service agreement with Baheal Pharmaceutical Group (SHE: 301015), a leading health services and distribution company in China. This collaboration will see Baheal provide exclusive market promotion services for Biostar’s novel cancer therapy, utidelone, across all medical institutions and drug retailing enterprises in mainland China.
Agreement Terms and Financials
Under the terms of the agreement, Baheal will make an upfront payment of RMB 50 million (USD 6.9 million) to Biostar. Additionally, Biostar will receive an undisclosed amount in R&D and marketing milestone payments, which are contingent upon the progress of research and development and sales activities. In return, Biostar will pay Baheal tiered promotion service fees based on the annual terminal sales of the product, creating a revenue-sharing model that aligns both parties’ interests.
Strategic Collaboration and Market Access
This strategic partnership leverages Baheal’s extensive network and experience in the Chinese healthcare market to enhance the market penetration of utidelone. The agreement not only provides Biostar with a robust platform for promoting its innovative cancer therapy but also ensures that Baheal remains at the forefront of offering cutting-edge treatments to patients and medical professionals in China.-Fineline Info & Tech
Leave a Reply